Subtype
Male Reproductive System Neoplasm
CI-CAN-00001107Explore in graph →
Non-malignant1,533 active trials27 approved drugs58 evidence items
- NCIt
- C3054
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001107Explore in graph →
Clinical trials
6,899 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00003173 | High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors | completed | Phase 2 | 36 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 7, 2013 | clinicaltrials |
| NCT01478308 | Metformin With Standard Taxotere and Prednisone in the Treatment of Castration Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | New Mexico Cancer Research AllianceOTHER | 0 | Mar 6, 2013 |
| NCT00103337 | Cilengitide in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 106 | National Cancer Institute (NCI)NIH | 1 | Feb 28, 2013 | clinicaltrials |
| NCT00757692 | Efficacy and Safety Study of Vandetanib (ZD 6474) in Combination With Bicalutamide Versus Bicalutamide Alone in Patients With Chemotherapy Naive Hormone Refractory Prostate Cancer. | completed | Phase 2 | 74 | British Columbia Cancer AgencyOTHER | 1 | Feb 20, 2013 | clinicaltrials |
| NCT00003256 | Flavopiridol in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00027599 | APC8015 and Bevacizumab in Treating Patients With Prostate Cancer | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Feb 11, 2013 | clinicaltrials |
| NCT00962494 | Cancer: Thriving and Surviving Online Workshop and Study for Cancer Survivors | completed | Phase 2 | 585 | Stanford UniversityOTHER | 2 | Feb 7, 2013 | clinicaltrials |
| NCT00265070 | Trial of Iressa in Prostate Cancer Patients | completed | Phase 2 | 80 | AstraZenecaINDUSTRY | 1 | Feb 5, 2013 | clinicaltrials |
| NCT00433446 | S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy | completed | Phase 2 | 62 | SWOG Cancer Research NetworkNETWORK | 1 | Feb 5, 2013 | clinicaltrials |
| NCT00040755 | BMS-275291 in Treating Patients With Prostate Cancer That Has Not Responded to Hormone Therapy | completed | Phase 2 | 68 | National Cancer Institute (NCI)NIH | 1 | Feb 1, 2013 | clinicaltrials |
| NCT00276549 | Gemcitabine and Docetaxel in Treating Patients With Metastatic Prostate Cancer | completed | Phase 2 | 35 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 31, 2013 | clinicaltrials |
| NCT00939510 | Lenalidomide and GM-CSF in Treating Patients With Prostate Cancer | completed | Phase 1 / Phase 2 | 32 | Robert Dreicer MDOTHER | 1 | Jan 31, 2013 | clinicaltrials |
| NCT00383487 | A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer | terminated | Phase 2 | 20 | Stanford UniversityOTHER | 1 | Jan 28, 2013 | clinicaltrials |
| NCT00003832 | Broxuridine Plus Surgery in Treating Patients With Stage I or Stage II Prostate Cancer | completed | Phase 2 | 75 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00096499 | SB-715992 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Docetaxel or Paclitaxel | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00005039 | Vaccine Therapy in Treating Patients With Advanced Adenocarcinoma of the Prostate (Prostate Cancer) | terminated | Phase 2 | 86 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00074022 | GTI-2040 and Docetaxel in Treating Patients With Recurrent, Metastatic, or Unresectable Locally Advanced Non-Small Cell Lung Cancer, Prostate Cancer, or Other Solid Tumors | completed | Phase 1 / Phase 2 | 48 | National Cancer Institute (NCI)NIH | 1 | Jan 24, 2013 | clinicaltrials |
| NCT00109811 | Vaccine Therapy in Treating Patients With Recurrent Prostate Cancer | completed | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00551122 | Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors(GemTIP) | unknown | Phase 1 / Phase 2 | 23 | University of SouthamptonOTHER | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00020891 | CT Scans in Guiding the Treatment of Patients With Prostate Cancer Who Are Undergoing Radiation Therapy | completed | Phase 2 | 25 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00147212 | ET 743 (Yondelis) in Men With Advanced Prostate Cancer | completed | Phase 2 | 50 | Massachusetts General HospitalOTHER | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00289341 | Safety and Effectiveness of a Vaccine for Prostate Cancer That Uses Each Patients' Own Immune Cells. | completed | Phase 1 / Phase 2 | 24 | Rockefeller UniversityOTHER | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00738673 | Degarelix as Second-Line Hormonal Treatment After Prostate-specific Antigen (PSA)-Failure in GnRH Agonist Treated Patients With Prostate Cancer | completed | Phase 2 | 37 | Ferring PharmaceuticalsINDUSTRY | 1 | Jan 18, 2013 | clinicaltrials |
| NCT00042952 | Imatinib Mesylate in Treating Patients With Progressive, Refractory, or Recurrent Stage II or Stage III Testicular or Ovarian Cancer | terminated | Phase 2 | 32 | National Cancer Institute (NCI)NIH | 1 | Jan 17, 2013 | clinicaltrials |
| NCT00014352 | Combination Chemotherapy Plus Warfarin in Treating Patients With Prostate Cancer | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00059943 | Docetaxel in Treating Older Patients With Metastatic Breast, Lung, or Prostate Cancer | completed | Phase 2 | — | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00071968 | Neoadjuvant CCI-779 Followed By Radical Prostatectomy in Treating Patients With Newly Diagnosed Prostate Cancer Who Have a High Risk of Relapse | completed | Phase 2 | 15 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jan 8, 2013 | clinicaltrials |
| NCT00090363 | ZD4054 (Zibotentan) in Pain-free or Mildly Symptomatic Patients With Prostate Cancer and Bone Metastases Who Have Rising Serum Prostate Specific Antigen (PSA) | completed | Phase 2 | 447 | AstraZenecaINDUSTRY | 14 | Jan 8, 2013 | clinicaltrials |
| NCT00299741 | Study of SU11248 in Men With Advanced Prostate Cancer | completed | Phase 2 | 36 | Massachusetts General HospitalOTHER | 1 | Dec 19, 2012 | clinicaltrials |
| NCT00564928 | A Phase 2 Study to Investigate the Clinical Activity of IPI-504 in Patients With Hormone-resistant Prostate Cancer(IPI-504-04) | completed | Phase 2 | 19 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Dec 11, 2012 | clinicaltrials |
| NCT00684905 | Leuprolide, Bicalutamide, and Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer After External-Beam Radiation Therapy | completed | Phase 2 | 50 | Mayo ClinicOTHER | 1 | Nov 12, 2012 | clinicaltrials |
| NCT01687049 | Red Yeast Rice in Subjects With Clinically Localized Prostate Cancer Undergoing Active Surveillance | unknown | Phase 2 | 60 | Dr. Laurence KlotzOTHER | 1 | Nov 7, 2012 | clinicaltrials |
| NCT00714376 | Phase II Study of Docetaxel for Clinically Asymptomatic High Risk Prostate Cancer Patients(TAX1) | terminated | Phase 2 | 6 | CHU de Quebec-Universite LavalOTHER | 1 | Oct 31, 2012 | clinicaltrials |
| NCT00084825 | Docetaxel and Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases That Progressed on the Docetaxel and Placebo Group of MDA-ID-030008 | completed | Phase 2 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 26, 2012 | clinicaltrials |
| NCT00078845 | Amifostine in Treating Peripheral Neuropathy Caused by Paclitaxel in Patients With Solid Tumors | completed | Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 17, 2012 | clinicaltrials |
| NCT00080678 | Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases | completed | Phase 2 | 116 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 12, 2012 | clinicaltrials |
| NCT00293371 | Docetaxel, Prednisone, and Vatalanib in Treating Patients With Advanced Prostate Cancer | terminated | Phase 1 / Phase 2 | 6 | University of California, San FranciscoOTHER | 1 | Oct 11, 2012 | clinicaltrials |
| NCT00327340 | Evaluation of Safety and Feasibility of OGX-011 in Combination With 2nd-line Chemotherapy in Patients With HRPC | completed | Phase 2 | 70 | Achieve Life SciencesINDUSTRY | 1 | Oct 5, 2012 | clinicaltrials |
| NCT00284752 | Phase II Trial of Abraxane in Front Line Therapy of Hormone Refractory Metastatic Prostate Cancer | completed | Phase 2 | 56 | Kaiser PermanenteOTHER | 1 | Oct 1, 2012 | clinicaltrials |
| NCT00006371 | A Phase II Trial of Early Medical Adrenalectomy for "D0.5" Prostate Cancer | terminated | Phase 2 | 2 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 27, 2012 | clinicaltrials |
| NCT00027794 | Radical Prostatectomy in Treating Patients With Locally Advanced Prostate Cancer | completed | Phase 2 | 40 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Sep 24, 2012 | clinicaltrials |
| NCT00065208 | Reiki/Energy Healing in Prostate Cancer | completed | Phase 1 / Phase 2 | 79 | The Cleveland ClinicOTHER | 1 | Sep 24, 2012 | clinicaltrials |
| NCT00066391 | Irinotecan and Cisplatin in Treating Patients With Locally Advanced or Metastatic Penile Cancer | completed | Phase 2 | — | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 6 | Sep 24, 2012 | clinicaltrials |
| NCT00085228 | Docetaxel With or Without Oblimersen in Treating Patients With Hormone-Refractory Adenocarcinoma (Cancer) of the Prostate | completed | Phase 2 | 116 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 11 | Sep 24, 2012 | clinicaltrials |
| NCT00617617 | The Specific Role of Isoflavones in Reducing Prostate Cancer Risk | completed | Phase 2 | 52 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 24, 2012 | clinicaltrials |
| NCT01663415 | A Study to Evaluate the Safety and Efficacy of Enzalutamide in Chemotherapy-Naïve, Symptomatic Patients With Metastatic Castration-Resistant Prostate Cancer | withdrawn | Phase 2 | 0 | Astellas Pharma Global Development, Inc.INDUSTRY | 0 | Sep 17, 2012 | clinicaltrials |
| NCT00004071 | Mitoxantrone and Prednisone With or Without Leflunomide in Treating Patients With Stage IV Prostate Cancer | completed | Phase 2 / Phase 3 | — | PfizerINDUSTRY | 1 | Sep 11, 2012 | clinicaltrials |
| NCT00081601 | Study of CEP-701 in Treatment of Prostate Cancer | completed | Phase 2 | 30 | CephalonINDUSTRY | 1 | Aug 24, 2012 | clinicaltrials |
| NCT00752739 | Selenium in Treating Patients With Prostate Cancer | completed | Phase 2 | 220 | University of ArizonaOTHER | 1 | Aug 15, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Mar 7, 2013source: clinicaltrials